Do you have pancreatic ductal adenocarcinoma that has come back after receiving standard therapy? If so, you may be able to participate in this gene therapy research study to learn more about using you own modified immune cells as possible treatment.

This study will evaluate the feasibility of using capillary blood samples collected with the Tasso device for analysis of CBC in diseased patients with leukemia, lymphoma, and/or other blood cell disorders.

The purpose of this research study is to learn more about the risk of severe and fatal infusion-related reactions (IRR) in patients with multiple myeloma who are treated with their first 3 administrations of daratumumab. Examples of severe IRR include lung tightness, low oxygen levels, difficulty breathing, high blood pressure, racing heart, headache, and too much fluid in the lungs. No fatal IRRs have been observed in clinical trials of daratumumab. We are also doing this study to help us to identify potential risk factors for IRR.

Have you been diagnosed with a B cell disease that has returned after your previous treatment or is not responding to your current treatment? If so, you might be able to take part in a study to see if a new treatment is safe and can help treat people with B-cell diseases.

Do you have Non-Small Cell Lung Cancer? Have you previously been treated with Osimertinib? If so, you may be eligible for a trial comparing osimertinib in combination with other medications to treat your lung cancer. Please reach out if you're interested!

Have you been diagnosed with early stage triple negative breast cancer? We are asking you to take part in this research study because you have been diagnosed with triple-negative breast cancer (TNBC) and have recently completed preoperative chemotherapy in combination with pembrolizumab, followed by breast surgery. The chemotherapy plus pembrolizumab produced a pathologic complete response (pCR), meaning that no remaining cancer was found during your breast surgery.

Have you been diagnosed with breast cancer? If so, you may be able to take part in a research study for the collection of tumor specimens and genomic DNA from patients with early or metastatic breast cancer.

Do you have stages 3-5 advance melanoma that is unresectable? Are you currently receiving standard therapy for your cancer? You may be able to participate in a research study to help us find out if your length of treatment could be reduced.

Do you Patients with have Advanced Nasopharyngeal Carcinoma that has Progressed After Platinum Treatment and Immunotherapy? If so, you may be able to participate in a research study to find out if progression-free survival of the triplet combination (CaboNivoIpi) is more favorable than the doublet (NivoIpi).

The purpose of this study is to find out whether a combination of drugs is a safe treatment for MGRS-associated kidney disease including cast nephropathy associated with multiple myeloma. The combination of drugs in this study is cyclophosphamide, bortezomib, dexamethasone (CyBorD) with daratumumab SC. In addition, we will find out whether the study drug combination is an effective treatment for these conditions.